Accreta, PlacentaNCT05972915
Separation Sign: New Ultrasound Sign to Rule Out Placenta Accreta
An observational study of Accreta, Placenta, run by Beni-Suef University at 1 site in Egypt.
Trial summary
To assess the 'separation sign' as a predictor of normal placental separation in a large cohort of women at risk for placenta accrete spectrum and in a high-risk subgroup with placenta previa or anterior low-lying placenta and have history of at least one previous Cesarean delivery. Read more about this study
- Who is it for?
- Ages 20 to 40 years, women only
- Conditions the study is for
- Accreta, Placenta
- What is being tested?
- Separation sign
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Jul 2023to 30 Nov 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- Adult
Study population: The study population includes high-risk cohort of women was defined as those who had placenta previa or an anterior low-lying placenta, in addition to at least one previous Cesarean delivery.
Who may be able to join
- History of previous cesarean section or hysterotomy.
- Placenta previa or low lying anterior placenta.
- From 28 wks to Full term.
Who cannot join
- Multiple pregnancies.
- Medical disorder as diabetes mellitus, hypertension. 3. Obese patients. BMI > 30 4. Intrauterine growth retardation.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Beni-suef university Hospital
Banī Suwayf, Beni Suweif Governorate, 62521
About this study
Official title: Separation Sign: New Ultrasound Sign to Rule Out Diagnosis of Placenta Accreta
To assess the 'separation sign' as a predictor of normal placental separation in a large cohort of women at risk for placenta accrete spectrum and in a high-risk subgroup with placenta previa or anterior low-lying placenta and have history of at least one previous Cesarean delivery.
Read the detailed description
A prospective Observational Cohort study The study population includes high-risk cohort of women was defined as those who had placenta previa or an anterior low-lying placenta, in addition to at least one previous Cesarean delivery. They will be asked to participate in the study after been evaluated to ensure fulfilling inclusion and exclusion criteria.
Women will be enrolled in the study after giving written informed consent
The patients will be submitted to:
**Full history taking including: Details of gestational age at the time of scanning, maternal age and risk factors , history of dilatation and curettage, in-vitro fertilization and other previous uterine surgery were assessed.
***Detailed trans-abdominal sonographic examination of the placenta was performed, assessing standard ultrasound markers of PAS. Two experienced sonographic operators performed all examinations using (Toshiba Xario 200) with 3D/4D curved-array trans-abdominal transducer (4-8.5 MHz). All examinations were performed with a full bladder, defined as a volume between 250mL 500mL quantified using the inbuilt ellipsoid volume calculation.
To assess for the separation sign, pressure was applied using an ultrasound probe so that the hypoechoic retroplacental clear zone normally observed between the placenta and myometrium disappeared. The pressure was then rapidly released in order to generate the force required to see movement. On release, in cases with normal placentation, the non-elastic placenta keeps moving away from the probe after the highly elastic myometrium has 'snapped' back into place. This sometimes causes the placenta either to keep moving briefly or even to 'bounce' and leads to the appearance or enhancement of the clear zone. With a negative separation sign, no separate movement of the placenta from the myometrium can be seen. The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta. Classification into positive or negative separation sign was highly stringent and, in case of any doubt, the result was recorded as uncertain. The latter occurred most often when the images obtained were suboptimal, for example, owing to tissue attenuation, high body mass index (BMI) or significant scarring. If women were scanned on multiple occasions, the separation sign result obtained closest to 28 weeks' gestation was used in order to minimize differences in scanning over the course of gestation.
***Based on histopathology results in cases in which hysterectomy was performed. A diagnosis of PAS was excluded if the placenta separated spontaneously at delivery, was delivered by controlled cord traction or was delivered by simple manual removal. Histopathological analysis was carried out by a pathologist with expertise in PAS, with the specific sampling site marked by the surgical team according to intrapartum findings. The pathologists were blinded to the separation sign classification but not to surgical findings.
- Conditions
- Accreta, Placenta
- Being tested
- Separation sign
- Keywords
- placenta accreta
- Medical subject headings
- Placenta Accreta
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Separation signDiagnostic test
The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta.
What is being measured
The primary outcome is the main question the study is designed to answer.
separation sign
The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta.
Measured: 1 month before delivery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Aug 2023
- Study start30 Jul 2023 (estimated)
- Primary completion30 Oct 2023 (estimated)
- Study completion30 Nov 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Accreta, PlacentaStudies of the same condition, open and under way.
- More trials run by Beni-Suef UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beni-Suef University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Abdallah Mohamed Salem, Beni-Suef University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05972915
- Sponsor's protocol ID
- Separation sign
- Status last verified
- Aug 2023
- First submitted
- 25 Jul 2023
- Last updated
- 2 Aug 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Separation Sign: New Ultrasound Sign to Rule Out Diagnosis of Placenta Accreta
- ClinicalTrials.gov ID
- NCT05972915
- Acronym / sponsor ID
- Separation sign
- Conditions
- Accreta, Placenta
- Keywords
- placenta accreta
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Beni-Suef UniversityUniversity, hospital or other
- Study start
- 30 Jul 2023 (estimated)
- Primary completion
- 30 Oct 2023 (estimated)
- Study completion
- 30 Nov 2023 (estimated)
- First posted
- 2 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess the 'separation sign' as a predictor of normal placental separation in a large cohort of women at risk for placenta accrete spectrum and in a high-risk subgroup with placenta previa or anterior low-lying placenta and have history of at least one previous Cesarean delivery.
Detailed description
A prospective Observational Cohort study The study population includes high-risk cohort of women was defined as those who had placenta previa or an anterior low-lying placenta, in addition to at least one previous Cesarean delivery. They will be asked to participate in the study after been evaluated to ensure fulfilling inclusion and exclusion criteria.
Women will be enrolled in the study after giving written informed consent
The patients will be submitted to:
**Full history taking including: Details of gestational age at the time of scanning, maternal age and risk factors , history of dilatation and curettage, in-vitro fertilization and other previous uterine surgery were assessed.
***Detailed trans-abdominal sonographic examination of the placenta was performed, assessing standard ultrasound markers of PAS. Two experienced sonographic operators performed all examinations using (Toshiba Xario 200) with 3D/4D curved-array trans-abdominal transducer (4-8.5 MHz). All examinations were performed with a full bladder, defined as a volume between 250mL 500mL quantified using the inbuilt ellipsoid volume calculation.
To assess for the separation sign, pressure was applied using an ultrasound probe so that the hypoechoic retroplacental clear zone normally observed between the placenta and myometrium disappeared. The pressure was then rapidly released in order to generate the force required to see movement. On release, in cases with normal placentation, the non-elastic placenta keeps moving away from the probe after the highly elastic myometrium has 'snapped' back into place. This sometimes causes the placenta either to keep moving briefly or even to 'bounce' and leads to the appearance or enhancement of the clear zone. With a negative separation sign, no separate movement of the placenta from the myometrium can be seen. The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta. Classification into positive or negative separation sign was highly stringent and, in case of any doubt, the result was recorded as uncertain. The latter occurred most often when the images obtained were suboptimal, for example, owing to tissue attenuation, high body mass index (BMI) or significant scarring. If women were scanned on multiple occasions, the separation sign result obtained closest to 28 weeks' gestation was used in order to minimize differences in scanning over the course of gestation.
***Based on histopathology results in cases in which hysterectomy was performed. A diagnosis of PAS was excluded if the placenta separated spontaneously at delivery, was delivered by controlled cord traction or was delivered by simple manual removal. Histopathological analysis was carried out by a pathologist with expertise in PAS, with the specific sampling site marked by the surgical team according to intrapartum findings. The pathologists were blinded to the separation sign classification but not to surgical findings.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Age groups
- Adult
- Study population
- The study population includes high-risk cohort of women was defined as those who had placenta previa or an anterior low-lying placenta, in addition to at least one previous Cesarean delivery.
Key inclusion criteria (3 listed)
- History of previous cesarean section or hysterotomy.
Key exclusion criteria (2 listed)
- Multiple pregnancies.
- Medical disorder as diabetes mellitus, hypertension. 3. Obese patients. BMI > 30 4. Intrauterine growth retardation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Separation signThe separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta. | Diagnostic test | – |
Primary outcome
separation sign
Time frame: 1 month before delivery
The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Aug 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Accreta, Placenta
Not yet recruitingObservational study
Placenta-Cervical Interface Angle for Predicting Placenta Accreta Spectrum Severity
Placenta Accreta Spectrum, Placenta Previa
Not yet recruitingObservational study
Hematological and Coagulation Markers in Predicting Placenta Accreta Spectrum in Placenta Previa
Placenta Accreta Spectrum, Placenta Previa
Not yet recruitingObservational study
Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum
Placenta Accreta, Third Trimester
Not yet recruitingObservational study
Total Lower Uterine Segmentectomy With Adjunctive Mechanical Towel Compression for the Surgical Management of Placenta Accreta Spectrum Disorders
Placenta Accreta Management
Recruiting
Comparison Between 3 Conservative Surgeries for Placenta Accreta Spectrum
Placenta Accreta Spectrum
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Accreta, Placenta, run by Beni-Suef University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Beni-suef University (082 2318605 ext. 02, fom@med.bsu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
separation sign (time frame: 1 month before delivery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2023.